Drugs / Convalescent anti-SARS-CoV-2 MBT Plasma
Convalescent anti-SARS-CoV-2 MBT Plasma
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04621123 | Nov 2020 → May 2021 | COVID-19 | Fight AIDS and Infectious Diseases Foundation | Completed | Missed primary |
| Phase 2 | NCT04547127 | Apr 2020 → Feb 2021 | COVID-19 | Grifols, S.A. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-02 | Grifols Therapeutics LLC | Results Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 grifols.com ↗
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people’s health and well-being, today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial, also known as INSIGHT-013, sponsored and supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its primary endpoints with statistically significant results. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-02 | Grifols Therapeutics LLC | Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 grifols.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Convalescent anti-SARS-CoV-2 MBT plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04621123 ↗ |
| Known as | CCP | “The negative efficacy results of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) as early treatment in the COnV-ert trial have been attributed to the use of...” PMID 41080591 ↗ Sep 2025 |
| Known as | convalescent plasma | “This is a prospective, randomized (1:1), double blind study of Convalescent anti-SARS-CoV-2 MBT Plasma (also known as convalescent plasma) plus standard medical treatment (SMT)...” NCT04621123 ↗ |
| Route | Intravenous | “Intravenous infusion.” NCT04547127 ↗ |